Multi‑kinase inhibitors and cisplatin for head and neck cancer treatment in vitro

Brands,Roman  C.; De Donno,Francesco; Knierim,Marie   Luise; Steinacker,Valentin; Hartmann,Stefan; Seher,Axel; Kübler,Alexander  C.; Müller‑Richter,Urs  D. A.

doi:10.3892/ol.2019.10541

Multi‑kinase inhibitors and cisplatin for head and neck cancer treatment in vitro

Authors:
- Roman C. Brands
- Francesco De Donno
- Marie Luise Knierim
- Valentin Steinacker
- Stefan Hartmann
- Axel Seher
- Alexander C. Kübler
- Urs D. A. Müller‑Richter
View Affiliations

Affiliations: Department of Oral and Maxillofacial Plastic Surgery, University Hospital Würzburg, D‑97070 Würzburg, Germany
Published online on: June 28, 2019 https://doi.org/10.3892/ol.2019.10541
Pages: 2220-2231
Copyright: © Brands et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug resistance (MDR) remains one of the major causes of suboptimal outcome following therapy in head and neck squamous cell carcinoma (HNSCC). ATP‑binding cassette (ABC) transporters are overexpressed in HNSCC, which contributes to the limited effect of chemotherapeutic treatment. In addition to their named function, tyrosine kinase inhibitors (TKIs) have been revealed to impact on ABC transporter activity and expression. Therefore, the present study aimed to investigate the effects of combination therapy using different TKIs combined with cisplatin. Reverse transcription‑quantitative PCR was used to characterize ABC transporter and receptor expression in 5 HNSCC cell lines treated with 3 different TKIs (pazopanib, dovitinib, nintedanib) and cisplatin. Treatment efficacy was analyzed using a crystal violet staining assay. Analysis of ABC transporter (ABCB1, ABCC1 and ABCG2) genetic alterations was performed using The Cancer Genome Atlas. Statistical analysis was conducted to evaluate the effects of mono‑ and combination treatment. With the exception of ABCB1, all of the investigated ABC transporters were expressed in each cell line. The additive effects of TKI + cisplatin combination treatment were observed for pazopanib in three cell lines, nintedanib in four cell lines, and were not observed for dovitinib in any of the cell lines investigated. The combination of multi‑kinase inhibitors and conventional chemotherapy in HNSCC may strengthen the use of current therapeutic strategies; nintedanib appears to be the most suitable TKI for combination therapy. Further efforts are required to classify TKI efficacy with regard to cisplatin resistance.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Anderson, Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
2	Langley RR and Fidler IJ: Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev. 28:297–321. 2007. View Article : Google Scholar : PubMed/NCBI
3	Ang KK, Chen A, Curran WJ Jr, Garden AS, Harari PM, Murphy BA, Wong SJ, Bellm LA, Schwartz M, Newman J, et al: Head and neck carcinoma in the United States: First comprehensive report of the longitudinal oncology registry of head and neck carcinoma (LORHAN). Cancer. 118:5783–5792. 2012. View Article : Google Scholar : PubMed/NCBI
4	Theile D, Gal Z, Warta R, Rigalli JP, Lahrmann B, Grabe N, Herold-Mende C, Dyckhoff G and Weiss J: Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma. Cancer Biol Ther. 15:436–442. 2014. View Article : Google Scholar : PubMed/NCBI
5	Fanucchi M and Khuri FR: Chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. Semin Oncol. 31:809–815. 2004. View Article : Google Scholar : PubMed/NCBI
6	Shen DW, Pouliot LM, Hall MD and Gottesman MM: Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
7	Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
8	Sauerbrey A, Sell W, Steinbach D, Voigt A and Zintl F: Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol. 118:147–150. 2002. View Article : Google Scholar : PubMed/NCBI
9	Borst P, Evers R, Kool M and Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 92:1295–1302. 2000. View Article : Google Scholar : PubMed/NCBI
10	Fletcher JI, Haber M, Henderson MJ and Norris MD: ABC transporters in cancer: More than just drug efflux pumps. Nat Rev Cancer. 10:147–156. 2010. View Article : Google Scholar : PubMed/NCBI
11	Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira RJ, Carvalho F, de Lourdes Bastos M and Remião F: Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther. 149:1–123. 2015. View Article : Google Scholar : PubMed/NCBI
12	Balkwill FR, Capasso M and Hagemann T: The tumor microenvironment at a glance. J Cell Sci. 125:5591–5596. 2012. View Article : Google Scholar : PubMed/NCBI
13	Hartmann S, Bhola NE and Grandis JR: HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. Clin Cancer Res. 22:4005–4013. View Article : Google Scholar : PubMed/NCBI
14	Quail DF, Taylor MJ and Postovit LM: Microenvironmental regulation of cancer stem cell phenotypes. Curr Stem Cell Res Ther. 7:197–216. 2012. View Article : Google Scholar : PubMed/NCBI
15	Miyake H, Hara I, Gohji K, Yoshimura K, Arakawa S and Kamidono S: Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett. 123:121–126. 1998. View Article : Google Scholar : PubMed/NCBI
16	Wakulich C, Jackson-Boeters L, Daley TD and Wysocki GP: Immunohistochemical localization of growth factors fibroblast growth factor-1 and fibroblast growth factor-2 and receptors fibroblast growth factor receptor-2 and fibroblast growth factor receptor-3 in normal oral epithelium, epithelial dysplasias, and squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 93:573–579. 2002. View Article : Google Scholar : PubMed/NCBI
17	Patel A, Tiwari AK, Chufan EE, Sodani K, Anreddy N, Singh S, Ambudkar SV, Stephani R and Chen ZS: PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells. Cancer Chemother Pharmacol. 72:189–199. 2013. View Article : Google Scholar : PubMed/NCBI
18	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
19	Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al: Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
20	Brands RC, Herbst F, Hartmann S, Seher A, Linz C, Kübler AC and Müller-Richter UDA: Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines. Clin Oral Investig. 20:2325–2332. 2016. View Article : Google Scholar : PubMed/NCBI
21	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
22	Brands RC, Knierim LM, De Donno F, Steinacker V, Hartmann S, Seher A, Kübler AC and Müller-Richter UDA: Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. Oncol Rep. 38:1877–1885. 2017. View Article : Google Scholar : PubMed/NCBI
23	Lee JG and Wu R: Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia. 17:190–200. 2015. View Article : Google Scholar : PubMed/NCBI
24	Tsang RY, Al-Fayea T and Au HJ: Cisplatin overdose: Toxicities and management. Drug Saf. 32:1109–1122. 2009. View Article : Google Scholar : PubMed/NCBI
25	Sweeny L, Zimmermann TM, Liu Z and Rosenthal EL: Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts. Oral Oncol. 48:1242–1249. 2012. View Article : Google Scholar : PubMed/NCBI
26	Homer JJ, Greenman J and Stafford ND: Angiogenesis in head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci. 25:169–180. 2000. View Article : Google Scholar : PubMed/NCBI
27	Cao Y: Antiangiogenic cancer therapy: Why do mouse and human patients respond in a different way to the same drug? Int J Dev Biol. 55:557–562. 2011. View Article : Google Scholar : PubMed/NCBI
28	Callaghan R: Providing a molecular mechanism for P-glycoprotein; why would I bother? Biochem Soc Trans. 43:995–1002. 2015. View Article : Google Scholar : PubMed/NCBI
29	Coyle B, Kessler M, Sabnis DH and Kerr ID: ABCB1 in children's brain tumours. Biochem Soc Trans. 43:1018–1022. 2015. View Article : Google Scholar : PubMed/NCBI
30	Hlaváč V and Souček P: Role of family D ATP-binding cassette transporters (ABCD) in cancer. Biochem Soc Trans. 43:937–942. 2015. View Article : Google Scholar : PubMed/NCBI
31	Chen CL, Sheen TS, Lou IU and Huang AC: Expression of multidrug resistance 1 and glutathione-S-transferase-Pi protein in nasopharyngeal carcinoma. Hum Pathol. 32:1240–1244. 2001. View Article : Google Scholar : PubMed/NCBI
32	Lo Muzio L, Staibano S, Pannone G, Mignogna MD, Serpico R, Rubini C, Fioroni M, Fanali S and Piattelli A: The human multidrug resistance gene (MDR-1): Immunocytochemical detection of its expression in oral SCC. Anticancer Res. 20:2891–2897. 2000.PubMed/NCBI
33	Uematsu T, Hasegawa T, Hiraoka BY, Komatsu F, Matsuura T, Yamada AS and Yamaoka M: Multidrug resistance gene 1 expression in salivary gland adenocarcinomas and oral squamous-cell carcinomas. Int J Cancer. 92:187–194. 2001. View Article : Google Scholar : PubMed/NCBI
34	Xiang QF, Wang F, Su XD, Liang YJ, Zheng LS, Mi YJ, Chen WQ and Fu LW: Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. Cell Oncol (Dordr). 34:33–44. 2011. View Article : Google Scholar : PubMed/NCBI
35	Weiss J, Theile D, Dvorak Z and Haefeli WE: Interaction potential of the multitargeted receptor tyrosine kinase inhibitor dovitinib with drug transporters and drug metabolising enzymes assessed in vitro. Pharmaceutics. 6:632–650. 2014. View Article : Google Scholar : PubMed/NCBI
36	Roche S, Pedersen K, Dunne G, Collins D, Devery A, Crown J, Clynes M and O'Connor R: Pharmacological interactions of TKIs with the P-gp drug transport protein. J Clin Oncol. 30:2536. 2012.
37	Atkinson A Jr, Huang SM, Lertora JJL and Markey SP: Principles of clinical pharmacology. 3. pp. 217–237. Academic Press; Cambridge, MA, USA: 2012
38	Mandery K, Glaeser H and Fromm MF: Interaction of innovative small molecule drugs used for cancer therapy with drug transporters. Br J Pharmacol. 165:345–362. 2012. View Article : Google Scholar : PubMed/NCBI
39	Galsky MD, Posner M, Holcombe RF, Lee KM, Misiukiewicz K, Tsao CK, Godbold J, Soto R, Gimpel-Tetra K, Lowe N and Oh WK: Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 74:465–471. 2014. View Article : Google Scholar : PubMed/NCBI